English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 12 November 2013, 22:20 HKT/SGT
Share:
    

Source: INC Research, LLC
INC Research Further Demonstrates Commitment to Drug Development Communities through Unveiling of New Brand Campaign
Company's "Can do, I own it" culture and insights from extensive market research drive renewed commitment to forging deeper connections across the clinical development process

Raleigh, NC, Nov 12, 2013 - (ACN Newswire) - INC Research, a therapeutically focused global clinical research organization (CRO) with a Trusted Process(R) for delivering reliable results, has unveiled a new brand campaign, "I am INC Research," that illustrates how the Company keeps customers, investigative sites and patients more connected throughout the entire clinical development process.

"Over the past two years, our Company has grown not only in size, but in scale and in therapeutic reach," said INC Research CEO Jamie Macdonald. "To further engage our employees in continuously improving the quality of our delivery to customers and create a 'Can do, I own it' culture, we took a hard look at ourselves and the perception of CROs as a whole. Every one of us that works at or with INC plays an integral role in developing the medicines that people need. As an industry, we all share this goal, but as a Company we discovered many of the practices we've implemented demonstrate a different way of doing business, one that resonates with our customers and the way they wish to be treated."

Working with market research company Industry Standard Research, INC Research conducted extensive primary research, including in-depth interviews with senior leaders from more than 120 mid-sized and large pharma customers in Europe and the United States. The research showed that CROs, in general, are viewed as not being as connected to the success of their sponsors' compounds as sponsors would like them to be. They also expressed a desire for CROs to show a greater sense of proactive involvement or "skin in the game."

"In an effort to better connect with our customers, we started to explore where we were different and found a common theme," explained Neil Ferguson, Executive Vice President, Global Business Development at INC Research. "We discovered that INC is able to fill a gap that exists in the market to drive deeper connections with drug development communities, a position we can uniquely own. Recognizing how powerful this is to our customers led us to develop our new brand campaign."

Among the key elements of the campaign is a brief video demonstrating how INC Research seamlessly connects with sites and investigators, customers, patients and data to ultimately bring new drugs to market for its customers and the patients served by the entire drug development community. The initial rollout also consists of a series of six advertisements, highlighting key roles and their connection with INC Research in delivering new therapies to patients.

"The end game is all about delivering new therapies to patients," continued Ferguson. "The common thread is that each and every person our customers interact with at INC Research is as connected and committed to their clinical trials and their compounds as they are. This sentiment is encapsulated in our new tagline: 'Developing the medicines people need is something we take personally.'"

To view how INC Research connects with customers, investigative sites and patients to bring new medicines to market on time and on budget, watch our powerful new film here (http://youtu.be/eafXrcwIaPQ). For more information on INC Research's new global brand campaign, visit www.incresearch.com.

About INC Research

INC Research is a therapeutically focused clinical research organization with a high-performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to us for a complete range of customized Phase I to IV programs in all therapeutic areas and patient populations. Our Trusted Process(R) methodology and therapeutic foresight lead customers to better-informed product development decisions, while our solid site relationships are a critical success factor in delivering clinical trial results on time and on budget. INC was ranked "Top CRO" by sites worldwide in the 2013 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, NC. For more information, please visit www.incresearch.com or follow us at @inc_research.

Contact:
Lori Dorer, Media +1-513-345-1685


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: INC RESEARCH, LLC via Thomson Reuters ONE

Topic: General Announcement
Source: INC Research, LLC


https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

INC Research, LLC Related News
Nov 7, 2014 08:50 HKT/SGT
INC Research Announces Pricing of Initial Public Offering
Oct 7, 2014 07:10 HKT/SGT
INC Research Files Registration Statement for Initial Public Offering
Oct 3, 2014 10:30 HKT/SGT
INC Research Demonstrates Continued Dedication to Site Relationships at 2014 SCRS Site Solutions Summit
Oct 2, 2014 07:20 HKT/SGT
INC Research Further Reinforces Commitment to Clinical Research Sites and Patients through Creation of New Leadership Role
Aug 6, 2014 03:30 HKT/SGT
INC Research's Tara Fitzgerald and Judy Swilley Named to Annual PharmaVOICE 100
More news >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575